摘要

Recently, studies have reported that aspirin has chemopreventive properties. In this study, we used the Taiwan NHI database, which covers a population of 23 million (99.99%) Taiwanese from 2001 to 2011. This was a case-control study which identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. Each case with 4 eligible controls was matched for age, sex, and index date and adjusted for confounding factors. The observed overall cancer risk (adjusted OR (AOR), 0.95; 95% CI 0.94 to 0.96) reduced with aspirin use, specifically, colorectal (AOR, 0.97; 95% CI 0.94 to 0.99) and digestive system (AOR, 0.96; 95% CI 0.94 to 0.98) cancers. Findings from the Asian population would contribute to the discussion on aspirin's safety profile.
原文英語
頁(從 - 到)391-392
頁數2
期刊Journal of Investigative Medicine
65
發行號2
DOIs
出版狀態已發佈 - 二月 1 2017

指紋

Aspirin
Digestive system
Digestive System
Neoplasms
International Classification of Diseases
Taiwan
Population
Case-Control Studies
Databases
Safety

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

引用此文

@article{232b0de8c57d453b8a32ba61c5dc59d1,
title = "Does aspirin use reduce the risk for cancer?",
abstract = "Recently, studies have reported that aspirin has chemopreventive properties. In this study, we used the Taiwan NHI database, which covers a population of 23 million (99.99{\%}) Taiwanese from 2001 to 2011. This was a case-control study which identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. Each case with 4 eligible controls was matched for age, sex, and index date and adjusted for confounding factors. The observed overall cancer risk (adjusted OR (AOR), 0.95; 95{\%} CI 0.94 to 0.96) reduced with aspirin use, specifically, colorectal (AOR, 0.97; 95{\%} CI 0.94 to 0.99) and digestive system (AOR, 0.96; 95{\%} CI 0.94 to 0.98) cancers. Findings from the Asian population would contribute to the discussion on aspirin's safety profile.",
author = "Iqbal Usman and Yang, {Hsuan Chia} and Jian, {Wen Shan} and Yun Yen and Li, {Yu Chuan}",
year = "2017",
month = "2",
day = "1",
doi = "10.1136/jim-2016-000275",
language = "English",
volume = "65",
pages = "391--392",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Does aspirin use reduce the risk for cancer?

AU - Usman, Iqbal

AU - Yang, Hsuan Chia

AU - Jian, Wen Shan

AU - Yen, Yun

AU - Li, Yu Chuan

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Recently, studies have reported that aspirin has chemopreventive properties. In this study, we used the Taiwan NHI database, which covers a population of 23 million (99.99%) Taiwanese from 2001 to 2011. This was a case-control study which identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. Each case with 4 eligible controls was matched for age, sex, and index date and adjusted for confounding factors. The observed overall cancer risk (adjusted OR (AOR), 0.95; 95% CI 0.94 to 0.96) reduced with aspirin use, specifically, colorectal (AOR, 0.97; 95% CI 0.94 to 0.99) and digestive system (AOR, 0.96; 95% CI 0.94 to 0.98) cancers. Findings from the Asian population would contribute to the discussion on aspirin's safety profile.

AB - Recently, studies have reported that aspirin has chemopreventive properties. In this study, we used the Taiwan NHI database, which covers a population of 23 million (99.99%) Taiwanese from 2001 to 2011. This was a case-control study which identified 601,733 patients using ICD-9-CM codes who were diagnosed with cancer. Each case with 4 eligible controls was matched for age, sex, and index date and adjusted for confounding factors. The observed overall cancer risk (adjusted OR (AOR), 0.95; 95% CI 0.94 to 0.96) reduced with aspirin use, specifically, colorectal (AOR, 0.97; 95% CI 0.94 to 0.99) and digestive system (AOR, 0.96; 95% CI 0.94 to 0.98) cancers. Findings from the Asian population would contribute to the discussion on aspirin's safety profile.

UR - http://www.scopus.com/inward/record.url?scp=85011408020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011408020&partnerID=8YFLogxK

U2 - 10.1136/jim-2016-000275

DO - 10.1136/jim-2016-000275

M3 - Article

VL - 65

SP - 391

EP - 392

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 2

ER -